ecrin-mdr-crcClinical2004Solid MalignanciesLymphoma, Non-HodgkinPancreatic cancerNon-Hodgkin's LymphomaColorectal cancerHead and neck cancerBreast cancerProstate cancerBladder cancerLymphomaNeoplasmsOvarian cancerOvarian CancerNon-hodgkin's LymphomaSolid MalignanciesColorectal CancerProstate CancerBladder CancerLymphoma, Non-hodgkinHead And Neck CancerPancreatic CancerLymphomaBreast CancerNeoplasmsInterventionalhttps://newmdr.ecrin.org/Study/2011348United States8DiffuseAcute myelogenous leukemiaChronic lymphocytic leukemiaAQ4NHypoxiaMetastaticFollicularECRIN MDRNot providedfalseChemotherapy for Patients With Advanced Solid Tumors or Non-Hodgkin’s LymphomaThe purposes of this study are to determine: * the largest dose of AQ4N that can be safely given once a week for three weeks out of a 4 week cycle * the side effects of AQ4N when given on the above schedule * how much AQ4N is in the blood and urine at specific times after administration and how the body get rids of AQ4N * if AQ4N helps treat cancer2004-08-152011348NCT00090727